Resultados de Búsqueda
Pertuzumab, in combination with trastuzumab and docetaxel, is recommended, within its marketing authorisation, for treating HER2‑positive metastatic or locally recurrent unresectable breast cancer, ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is for a drug that has been available on the Cancer Drugs Fund for several years and the committee recognised this as an exceptional circumstance. In this context, the committee considered it reasonable to apply flexibility in its interpretation of the criteria for special consideration as a life-extending treatment for people with a short life expectancy, but noted that the weight applied to the quality-adjusted life years gained would not be at the maximum allocated in ...
ver más ... 2018Fulvestrant is not recommended, within its marketing authorisation, for treating locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women who have not had ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with Fulvestrant that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. People with untreated disease are first offered an aromatase inhibitor, either anastrozole or letrozole. These drugs are considered ...
ver más ... 2018The Intrabeam radiotherapy system is not recommended for routine commissioning for adjuvant treatment of early invasive breast cancer during breast-conserving surgical removal of the tumour.
NICE
National Institute for Health and Clinical Excellence (NICE)
Use of the Intrabeam radiotherapy system is recommended only using machines that are already available and in conjunction with NHS England specified clinical governance, data collection and submission arrangements. The procedure should only be carried out by clinicians with specific training in the use of the Intrabeam radiotherapy system. Patient selection for Intrabeam radiotherapy should be done by a multidisciplinary team experienced in the management of early invasive breast cancer, ...
ver más ... 2018It is recommended to Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless MRI is ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Refer people with a suspected glioma to a specialist multidisciplinary team at first radiological diagnosis for management of their tumour. Consider advanced MRI techniques, such as MR perfusion and MR spectroscopy, to assess the potential of a high-grade transformation in a tumour appearing to be low grade on standard structural MRI.
ver más ... 2018Vandetanib is not recommended, within its marketing authorisation, for treating aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with vandetanib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Vandetanib and cabozantinib are the only systemic treatment options for unresectable, locally advanced or metastatic medullary ...
ver más ... 2018